Detalhe da pesquisa
1.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Mol Ther
; 31(11): 3176-3192, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37766429
2.
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
Mol Ther
; 30(9): 2998-3016, 2022 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35526097
3.
Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy.
Mol Ther Oncolytics
; 25: 146-159, 2022 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35572196
4.
A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity.
Cancers (Basel)
; 14(12)2022 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35740500
5.
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
Front Immunol
; 13: 1032356, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36532027
6.
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern.
ACS Infect Dis
; 7(11): 3034-3051, 2021 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34658235